drugset
drugset / Trial / NCT02090933

Celecoxib in Decreasing the Damaging Effects of Sunburn in Healthy Volunteers

NCT02090933 ↗

Phase 2 Completed 25 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelPrevention

Summary

This clinical trial studies celecoxib in decreasing the damaging effects of sunburn in healthy volunteers. Celecoxib may reduce skin damage by blocking enzymes associated with sunburn in healthy volunteers.

Timeline

Start
2004-03
Primary completion
2004-12
Completion
2004-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Celecoxib Other / unclassified — Oral

Indications

No indication recorded.